Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Surufatinib in locally advanced thyroid cancer
NCT04524884Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, surufatinib in differentiated thyroid cancer (DTC), sponsored by Fudan University. Status: unknown.
02
Drugs
toripalimabsurufatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04524884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524884.